Literature DB >> 24751616

Pure trisomy 2p syndrome in two siblings with an unbalanced translocation and minimal terminal 12q monosomy characterized by high-density microarray.

Alejandro Martínez-Juárez1, Laura Uribe-Figueroa, Mónica Quintana-Palma, Guadalupe Razo-Aguilera, Rosalba Sevilla-Montoya.   

Abstract

Pure partial trisomy 2p patients have rarely been reported. Oligonucleotide array analysis has proved to be important for examining 2p rearrangements to delineate the involved segment and to rule out additional imbalances modifying the phenotype. Here, we report 2 siblings with an unbalanced translocation that led to a partial trisomy 2p (p22.3pter) and a terminal deletion of 12q (q24.33qter). This finding was characterized by the molecular karyotyping of both siblings. The 12q loss spanned approximately 300 kb and did not yield clinical features in our patients. The trisomic region in the short arm of chromosome 2 spanned 32.8 Mb and yielded phenotypic features of pure distal 2p trisomy, notably facial anomalies, growth failure, and psychomotor delay. The clinical features of our patients help to delineate the phenotype of the pure trisomy 2p syndrome. Patient 2 also showed a horseshoe kidney which is a previously unrecognized defect associated with this syndrome.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2014        PMID: 24751616     DOI: 10.1159/000362141

Source DB:  PubMed          Journal:  Cytogenet Genome Res        ISSN: 1424-8581            Impact factor:   1.636


  2 in total

1.  A Two-Month-Old Child with Vascular Ectasia: A Case Report Diagnosed by Molecular Karyotyping.

Authors:  Ozlem Tolu Kendir; Hayri Levent Yilmaz; Sevcan Bozdogan; Atıl Bisgin; Tugçe Celik; Ozgur Surmelioglu; Figen Doran
Journal:  J Pediatr Genet       Date:  2018-08-22

2.  Duplication 2p25 in a child with clinical features of CHARGE syndrome.

Authors:  Ethan D Sperry; Jane L Schuette; Conny M A van Ravenswaaij-Arts; Glenn E Green; Donna M Martin
Journal:  Am J Med Genet A       Date:  2016-02-06       Impact factor: 2.802

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.